{'fraction_non_alphanumeric': 0.031098825155494125, 'fraction_numerical': 0.019350380096751902, 'mean_word_length': 5.109704641350211, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Determination of galectin-3, hepsin and thyroid transcription factor-1 levels in thyroid cancer patients; A prospective case-control study

Aim: We aimed to evaluate the usage of Galectin-3, Hepsin andTTF-1 levels as a marker for the differentiation of malignant and benign in patients with thyroid nodules. Metods: Study was done prospectively between January 2018 and April 2018 in the our clinic, in patients planned for operation due to thyroid nodule. Galectin-3, Hepsin andTTF-1 levels were measured in the pre-operative serum of the benign and malign groups. The measured levels are evaluated statistically to determine whether there was any significant difference between malignant and benign groups. Results: When the levels of Galectin-3, Hepsin andTTF-1 in the malign and benign group were compared; There was a statistically significant difference inTTF-1 levels(p = .038), no significant difference was found in Hepsin and Galectin-3. When the macropapillary and micropapillary types were compared in the malign patient group, there was a significant difference between the Galectin-3 levels(p = .009), but no difference was found between Hepsin andTTF-1. Conclusions: It was seen that the decrease of Galectin-3 level in thyroid papillary carcinoma could be effective in transformation from micro carcinoma to macro carcinoma, andTTF-1 could be an important marker at the differentiation between benign and  malign in thyroid nodules